Anti-EGFR (epidermal growth factor receptor) therapies, such as Cetuximab, are chimeric monoclonal antibodies widely used to curb colorectal cancer metastasis by blocking the activation of EGFR tyrosine kinases, thereby preventing further cell proliferation. The gene discussed is EGFR; the disease is colorectal cancer.